RedHill Biopharma Ltd. (RDHL) stock
RDHLNasdaqPharmaceutical Preparations
$0.38−0.01 (-1.60%)
Close on Nov 13, 2026Market cap $1.91MP/E –Yield –
RedHill Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $2.02M, up 27.4% from the year before. Over ten years it grew -19.5% a year on average. The highest annual figure on record is $32.97M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.02M | +27.4% |
| FY2024 | Dec 31, 2024 | $1.59M | -55.0% |
| FY2023 | Dec 31, 2023 | $3.53M | -51.5% |
| FY2022 | Dec 31, 2022 | $7.28M | -75.3% |
| FY2021 | Dec 31, 2021 | $29.50M | +78.9% |
| FY2020 | Dec 31, 2020 | $16.49M | -5.3% |
| FY2019 | Dec 31, 2019 | $17.42M | -29.9% |
| FY2018 | Dec 31, 2018 | $24.86M | -24.6% |
| FY2017 | Dec 31, 2017 | $32.97M | +30.6% |
| FY2016 | Dec 31, 2016 | $25.24M | +42.0% |
| FY2015 | Dec 31, 2015 | $17.77M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | $1.47M | -75.6% |
| Q2 FY2021 | Jun 30, 2021 | $10.33M | +22.5% |
| Q2 FY2020 | Jun 30, 2020 | $3.21M | – |
| Q2 FY2019 | Jun 30, 2019 | $6.97M | – |
| Q2 FY2018 | Jun 30, 2018 | $6.04M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.43M | – |
See a number that looks wrong?